Linden Thomas Advisory Services’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
Linden Thomas Advisory Services's CORT Position: Q3 2026 in Review
Linden Thomas Advisory Services reduced its Corcept Therapeutics (CORT) stake by 0.91% in Q3 2026, selling an estimated $33.9K and leaving 34,326 shares worth $3.96M. The position accounts for 0.31% of the portfolio, ranked #85.
Linden Thomas Advisory Services first reported a position in CORT in Q2 2023 and has held it in 14 quarters since. The position peaked at $7.27M in Q1 2025. 93 funds tracked by Wall St. Rank hold CORT as of Q3 2026.
- Linden Thomas Advisory Services held 34,326 shares of Corcept Therapeutics worth $3.96M as of Q3 2026.
- Linden Thomas Advisory Services sold 315 Corcept Therapeutics shares in Q3 2026, an estimated $33.9K.
- Corcept Therapeutics made up 0.31% of Linden Thomas Advisory Services's portfolio in Q3 2026, its #85 holding.
- Linden Thomas Advisory Services first reported a position in Corcept Therapeutics in Q2 2023 and has held it in 14 quarters since.
- Linden Thomas Advisory Services's Corcept Therapeutics position peaked at $7.27M in Q1 2025.
- 93 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.
Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.